This paper is in the following e-collection/theme issue:

Authors' Responses to Peer-Reviews (92)

Published on in Vol 2, No 3 (2021): Jul-Sep

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/33496, first published .
Authors' Response to Peer Reviews of “Early Experience With Neutralizing Monoclonal Antibody Therapy for COVID-19: Retrospective Cohort Survival Analysis and Descriptive Study”

Authors' Response to Peer Reviews of “Early Experience With Neutralizing Monoclonal Antibody Therapy for COVID-19: Retrospective Cohort Survival Analysis and Descriptive Study”

Authors' Response to Peer Reviews of “Early Experience With Neutralizing Monoclonal Antibody Therapy for COVID-19: Retrospective Cohort Survival Analysis and Descriptive Study”

Authors of this article:

Mark Jarrett1 Author Orcid Image ;   Warren Licht1 Author Orcid Image ;   Kevin Bock1 Author Orcid Image ;   Zenobia Brown1 Author Orcid Image ;   Jamie Hirsch1 Author Orcid Image ;   Kevin Coppa2 Author Orcid Image ;   Rajdeep Brar1 Author Orcid Image ;   Stephen Bello2 Author Orcid Image ;   Ira Nash1 Author Orcid Image
Article Authors Cited by Tweetations (2) Metrics

    Authors' Response to Peer Reviews

    1Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hofstra University, Hempstead, NY, United States

    2Northwell Health, New Hyde Park, NY, United States

    *all authors contributed equally

    Corresponding Author:

    Mark Jarrett, MBA, MD

    Donald and Barbara Zucker School of Medicine at Hofstra/Northwell

    Hofstra University

    500 Hofstra University

    Hempstead, NY, 11549

    United States

    Phone: 1 516 463 7516

    Email: mjarrett@northwell.edu


    JMIRx Med 2021;2(3):e33496

    doi:10.2196/33496

    Keywords

    infectious disease; monoclonal antibody therapy; COVID-19; experience; therapy; drug; patient outcome; risk; efficacy; approach; treatment; pandemic; antibody; immunotherapy; immune therapy 

    This is the authors’ response to peer-review reports for “Early Experience With Neutralizing Monoclonal Antibody Therapy for COVID-19: Retrospective Cohort Survival Analysis and Descriptive Study.”


    1. Formatting in paper [2] changed as requested
    2. Figures changed
    3. Added suggested contextualization
    4. Fortified Discussion
    5. Although we added references and discussion of the inflammatory response to cytokines, it should be recognized that these antibodies work by neutralization of the virus, not by affecting cytokines.
    1. Anonymous. Peer review of "Early Experience With Neutralizing Monoclonal Antibody Therapy for COVID-19: Retrospective Cohort Survival Analysis and Descriptive Study". JMIRx Med 2021 Sep;2(3):e33499 [https://med.jmirx.org/2021/3/e33499/]
    2. Jarrett M, Licht W, Bock K, Brown Z, Hirsch J, Coppa K, et al. Early experience with neutralizing monoclonal antibody therapy for COVID-19: retrospective cohort survival analysis and descriptive study. JMIRx Med 2021 Sep;2(3):e29638 [https://med.jmirx.org/2021/3/e29638/]

    Edited by E Meinert; This is a non–peer-reviewed article. submitted 09.09.21; accepted 09.09.21; published 27.09.21

    Copyright

    ©Mark Jarrett, Warren Licht, Kevin Bock, Zenobia Brown, Jamie Hirsch, Kevin Coppa, Rajdeep Brar, Stephen Bello, Ira Nash. Originally published in JMIRx Med (https://med.jmirx.org), 27.09.2021.

    This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIRx Med, is properly cited. The complete bibliographic information, a link to the original publication on https://med.jmirx.org/, as well as this copyright and license information must be included.